

Dupilumab cuts exacerbations in late-onset asthma

May 21 2019



(HealthDay)—Dupilumab is associated with significantly reduced severe

exacerbation rates in patients with late-onset asthma with or without fixed airway obstruction, according to a study presented at the American Thoracic Society 2019 International Conference, held from May 17 to 22 in Dallas.

Nicola Alexander Hanania, M.D., from the Baylor College of Medicine in Houston, and [colleagues](#) examined the efficacy of dupilumab in [patients](#) with late-onset asthma and with baseline postbronchodilator forced expiratory volume in one second/forced vital capacity (FEV₁/FVC) ratio

Citation: Dupilumab cuts exacerbations in late-onset asthma (2019, May 21) retrieved 17 July 2024 from <https://medicalxpress.com/news/2019-05-dupilumab-exacerbations-late-onset-asthma.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.